Drug interactions
Istradefylline + Linagliptin-metformin
Severity: Minor
Istradefylline and Linagliptin-metformin: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
At higher doses istradefylline inhibits CYP3A4 and P-glycoprotein and may raise linagliptin concentrations. Linagliptin has a wide therapeutic margin, so the clinical effect is expected to be limited.
What this interaction means in plain words
Istradefylline and Linagliptin-metformin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Istradefylline belongs to Central Nervous System; Linagliptin-metformin belongs to Endocrine.
Why it happens
Inhibition of CYP3A4 and P-glycoprotein at higher istradefylline doses increases linagliptin exposure.
What to do
No routine dose change is needed; monitor for hypoglycemia or adverse effects if istradefylline 40 mg/day is used.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Istradefylline and Linagliptin-metformin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Linagliptin-metformin
Other interactions of Istradefylline
Frequently asked questions
Can I take Istradefylline with Linagliptin-metformin?
MediHelp rates the interaction as minor. Istradefylline and Linagliptin-metformin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. At higher doses istradefylline inhibits CYP3A4 and P-glycoprotein and may raise linagliptin concentrations. Linagliptin has a wide therapeutic margin, so the clinical effect is expected to be limited.
How serious is the interaction between Istradefylline and Linagliptin-metformin?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No routine dose change is needed; monitor for hypoglycemia or adverse effects if istradefylline 40 mg/day is used.
What other medicines interact with Linagliptin-metformin?
MediHelp also lists interactions of Linagliptin-metformin with, for example, Apalutamide, Carbamazepine, Contrast media. The full list is on the Linagliptin-metformin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
